Merck & Co. (NYSE:MRK): Current price $46.10
Merck Sharp and Dohme has brought a lawsuit against Mumbai-based Glenmark Pharmaceuticals in the Delhi High Court, claiming violation of its patent for blockbuster anti-diabetes drugs Januvia and Janumet, says The Business Standard.
Pfizer (NYSE:PFE): Current price $28.96
Tetragenetics has reached a collaboration agreement with an option with Pfizer for an exclusive license for SionX. The SionX tech allows high density expression of recombinant human ion channels on the cell membranes of Tetrahymena thermophila. Immunogen preparations of the ion channel are created to enhance antibody production against the extracellular portions of the ion channel target.
AT&T (NYSE:T): Current price $37.30
If AT&T (NYSE:T) were to become involved in a Vodafone Group (NASDAQ:VOD) deal with Verizon, it could prove to be an expensive call, reports The Wall Street Journal’s Heard on the Street. Chatter has it that the timing could soon be right for Verizon to acquire the 45 percent of Verizon Wireless owned by London-based Vodafone, or just purchase Vodafone itself. However, in a late-Tuesday Securities and Exchange Commission Exhibit 99, Verizon states that it is not interested in a purchase of Vodafone at this time.
Don’t Miss: Are These the 5 Best Stocks for Earnings Season?